{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:26:49Z","timestamp":1787585209244,"version":"build-2736575974"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Health Digital Twins (HDTs) have attracted increasing interest as a potential tool for improving both patient care and clinical research, particularly in oncology where clinical trials remain slow, costly, and operationally complex. This primer introduces the concept of digital twins in a form accessible to professionals involved in oncology clinical research and outlines the main components of health digital twins, describes how these systems are generated, and highlights their potential relevance to oncology trials. HDTs are personalized, dynamically updated, predictive, and decision\u2212informing computational representations that integrate clinical records, laboratory measurements, imaging, pathology, and molecular data. The generation of an HDT begins with the integration of multiple sources of information to create a digital representation that reflects the patient\u2019s disease state and can be updated as new information becomes available. These systems may be built using data\u2212driven AI models, mechanistic physiological models, or hybrid approaches that combine both. Emerging HDT\u2212based approaches have been proposed as a means of addressing several of the structural limitations of oncology trials by enabling in\u2212silico experimentation, improved biological stratification of patients, and more efficient use of longitudinal real\u2212world and historical data. In early\u2212phase studies, HDTs can support dose selection, safety evaluation, and cohort selection, while in later phases they may contribute to optimized trial designs, synthetic control arms, and adaptive trial methodologies. These applications may reduce patient enrolment time, improve efficiency, and support simulation\u2212driven decision\u2212making. Despite this promise, the application of HDTs remains associated with technical, ethical, regulatory, and data\u2212governance challenges, including data quality, model validity, bias, and uncertainty. Regulatory agencies currently view HDTs as complementary tools within model\u2212informed drug development rather than as replacements for conventional clinical evidence. In conclusion, HDTs have the potential to transform clinical trials by enabling personalized treatments, optimizing trial design, and facilitating predictive analytics, although their applications remain emerging and require further validation, governance frameworks, and regulatory alignment to support widespread adoption.<\/jats:p>","DOI":"10.3389\/fonc.2026.1885797","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:41:51Z","timestamp":1787582511000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Role of health digital twins in oncology drug development -\u00a0a primer"],"prefix":"10.3389","volume":"16","author":[{"given":"Maria","family":"Garcia Requesens","sequence":"first","affiliation":[{"name":"Fortrea Inc.","place":["Durham, NC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun K.","family":"Mankan","sequence":"additional","affiliation":[{"name":"Fortrea Inc.","place":["Durham, NC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cantini","sequence":"additional","affiliation":[{"name":"Fortrea Inc.","place":["Durham, NC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Calabresi","sequence":"additional","affiliation":[{"name":"Fortrea Inc.","place":["Durham, NC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Vidal","sequence":"additional","affiliation":[{"name":"Fortrea Inc.","place":["Durham, NC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Brown","sequence":"additional","affiliation":[{"name":"Fortrea Inc.","place":["Durham, NC, United States"]},{"name":"Clinical Surgery, Keck School of Medicine","place":["Los Angeles, LA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Lang","sequence":"additional","affiliation":[{"name":"Fortrea Inc.","place":["Durham, NC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobby","family":"Kaura","sequence":"additional","affiliation":[{"name":"Pathway Bio","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirill","family":"Veselkov","sequence":"additional","affiliation":[{"name":"Department of Computational Medicine, Imperial College","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Xenarios","sequence":"additional","affiliation":[{"name":"TwinEdge Biosciences","place":["Lausanne, Switzerland"]},{"name":"University of Lausanne","place":["Lausanne, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal S.","family":"Saini","sequence":"additional","affiliation":[{"name":"Fortrea Inc.","place":["Durham, NC, United States"]},{"name":"Department of Medical Oncology, Cambridge University Hospitals NHS Foundation Trust","place":["Cambridge, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01030","article-title":"National estimates of the participation of patients with cancer in clinical research studies based on commission on cancer accreditation data","volume":"42","author":"Unger","year":"2024","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat Biotechnol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.17226\/26894","article-title":"Time to raise the bar: transition rate of phase 1 programs on anticancer drugs","volume":"40","author":"Gong","year":"2022","journal-title":"Cancer Cell"},{"key":"B4","article-title":"Foundational Research Gaps and Future Directions for Digital Twins","author":"Green","year":"2024"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2026.105171","article-title":"Digital twins in oncology: from predictive modelling to personalised treatment strategies","volume":"220","author":"Olawade","year":"2026","journal-title":"Crit Rev Oncol Hematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.landig.2025.01.007","article-title":"Digital twins, synthetic patient data, and in-silico trials: can they empower paediatric clinical trials","volume":"7","author":"Pammi","year":"2025"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2410","article-title":"Feasibility of using population pharmacokinetics\u2010based virtual control groups in organ impairment studies","volume":"64","author":"Younis","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-022123-022046","article-title":"Health digital twins in life science and health care innovation","volume":"64","author":"Venkatesh","year":"2024","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41746-024-01073-0","article-title":"Digital twins for health: a scoping review","volume":"7","author":"Katsoulakis","year":"2024","journal-title":"NPJ Digit Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"100864","DOI":"10.1016\/j.landig.2025.02.004","article-title":"Medical digital twins: enabling precision medicine and medical artificial intelligence","volume":"7","author":"Sad\u00e9e","year":"2025","journal-title":"Lancet Digit Health"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0090","article-title":"Artificial intelligence in cancer research and precision medicine","volume":"11","author":"Bhinder","year":"2021","journal-title":"Cancer Discov"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/3676295","article-title":"Mechanistic model for cancer growth and response to chemotherapy","volume":"2017","author":"Simbawa","year":"2017","journal-title":"Comput Math Methods Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmorw.2024.100056","article-title":"Digital twins: a new paradigm in oncology in the era of big data","volume":"5","author":"Mollica","year":"2024","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01564","article-title":"Long-term performance of an image-based short-term risk model for breast cancer","volume":"41","author":"Eriksson","year":"2023","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"135035","DOI":"10.1088\/1361-6560\/ae835a","article-title":"A digital twin framework for adaptive treatment planning in radiotherapy","volume":"71","author":"Chang","year":"2026","journal-title":"Phys Med Biol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s10796-024-10536-4","article-title":"A conceptual framework for digital twin in healthcare: evidence from a systematic meta-review","volume":"27","author":"Pellegrino","year":"2025","journal-title":"Inf Syst Front"},{"key":"B17","article-title":"Digital twins grow up but adoption hurdles remain","volume-title":"In Vivo","author":"Wild","year":"2025"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/frai.2023.1222612","article-title":"Predictive digital twin for optimizing patient-specific radiotherapy regimens under uncertainty in high-grade gliomas","volume":"6","author":"Chaudhuri","year":"2023","journal-title":"Front Artif Intell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222733","article-title":"Comparison of mammography AI algorithms with a clinical risk model for 5-year breast cancer risk prediction: an observational study","volume":"307","author":"Arasu","year":"2023","journal-title":"Radiology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/pnasnexus\/pgaf123","article-title":"The future of in silico trials and digital twins in medicine","volume":"4","author":"Samei","year":"2025","journal-title":"PNAS Nexus"},{"key":"B21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41540-025-00592-0","article-title":"Enhancing randomized clinical trials with digital twins","volume":"11","author":"Akbarialiabad","year":"2025","journal-title":"NPJ Syst Biol Appl"},{"key":"B22","unstructured":"Digital twins part 1: introduction. Technical Bulletin, Issue 118: Office of Research Facilities (ORF), National Institutes of Health (NIH)\n          \n          \n          2021"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01558-5","article-title":"Digital twins for predictive oncology will be a paradigm shift for precision cancer care","volume":"27","author":"Hernandez-Boussard","year":"2021","journal-title":"Nat Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41746-025-01910-w","article-title":"A scoping review of human digital twins in healthcare applications and usage patterns","volume":"8","author":"Tudor","year":"2025","journal-title":"NPJ Digit Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41746-025-01447-y","article-title":"Survey and perspective on verification, validation, and uncertainty quantification of digital twins for precision medicine","volume":"8","author":"Sel","year":"2025","journal-title":"NPJ Digit Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1186\/s13063-021-05489-x","article-title":"The role of machine learning in clinical research: transforming the future of evidence generation","volume":"22","author":"Weissler","year":"2021","journal-title":"Trials"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.48550\/ARXIV.2601.01321","article-title":"Digital twin AI: opportunities and challenges from large language models to world models","author":"Zhou","year":"2026","journal-title":"arXiv"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaf237","article-title":"Advances and critical aspects in cancer treatment development using digital twins","volume":"26","author":"Bouriga","year":"2025","journal-title":"Brief Bioinform"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djad228","article-title":"RE: use of artificial intelligence for cancer clinical trial enrollment","volume":"116","author":"Deng","year":"2024","journal-title":"JNCI J Natl Cancer Inst"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-1199","article-title":"Artificial intelligence in oncology: current landscape, challenges, and future directions","volume":"14","author":"Lotter","year":"2024","journal-title":"Cancer Discov"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2025-000893","article-title":"Digital twins in oncology: where we are and where we hope to go","volume":"4","author":"McCoy","year":"2025","journal-title":"BMJ Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1005874","article-title":"Mechanistic modeling quantifies the influence of tumor growth kinetics on the response to anti-angiogenic treatment","volume":"13","author":"Gaddy","year":"2017","journal-title":"PloS Comput Biol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2025.1434739","article-title":"In silico oncology: a mechanistic multiscale model of clinical prostate cancer response to external radiation therapy as the core of a digital (virtual) twin. Sensitivity analysis and a clinical adaptation approach","volume":"16","author":"Stamatakos","year":"2025","journal-title":"Front Physiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00850-7","article-title":"Application of digital twins for personalized oncology","volume":"25","author":"Asghar","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B36","article-title":"Roadmap to reducing animal testing in preclinical safety studies","year":"2025"},{"key":"B37","article-title":"ICH M15 guideline on general principles for model-informed drug development (step 5)","year":"2026"},{"key":"B38","article-title":"Model-informed drug development paired meeting program","year":"2026"},{"key":"B39","article-title":"M15 general principles for model-informed drug development: guidance for industry","year":"2026"},{"key":"B40","article-title":"Concept paper on the development of a guideline on assessment and reporting of mechanistic models used in the context of model-informed drug development","year":"2025"},{"key":"B41","article-title":"AI in oncology: transforming cancer detection through machine learning and deep learning applications","author":"Aftab","year":"2025","journal-title":"arXiv"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2024.08.002","article-title":"The use of digital healthcare twins in early-phase clinical trials","volume":"9","author":"Mann","year":"2024","journal-title":"JACC Basic Transl Sci"},{"key":"B43","article-title":"New approach methodologies (NAMs)","year":""},{"key":"B44","article-title":"FDA releases draft guidance on alternatives to animal testing in drug development","year":"2026"},{"key":"B45","unstructured":"FDA Modernization Act 2.0: an act to allow for alternatives to animal testing for purposes of drug and biological product applications. Report S.5002\n          \n          \n          \n          2022"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1885797\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:41:52Z","timestamp":1787582512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1885797\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":45,"alternative-id":["10.3389\/fonc.2026.1885797"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1885797","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"article-number":"1885797"}}